科拓生物(300858) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥100,988,785.61, a decrease of 2.64% compared to the same period last year, while year-to-date revenue increased by 10.01% to ¥268,295,524.00[3] - Net profit attributable to shareholders for Q3 2021 was ¥40,239,800.67, an increase of 18.52% year-on-year, with a year-to-date net profit of ¥84,830,878.68, up 16.95%[3] - Total revenue for Q3 2021 reached ¥268,295,524, an increase of 10.5% compared to ¥243,871,977 in Q3 2020[23] - Operating profit for Q3 2021 was ¥94,074,340, up from ¥89,505,458 in the same period last year, reflecting a growth of 6.0%[23] - Net profit for Q3 2021 was ¥84,830,878, representing a 16.9% increase from ¥72,534,281 in Q3 2020[24] Earnings and Shares - The basic earnings per share for Q3 2021 was ¥0.27, reflecting an increase of 8.00% compared to the same period last year[3] - Basic earnings per share for Q3 2021 were 0.57, down from 0.61 in the previous period[25] - The total number of shares outstanding as of the report date was 148,531,845, reflecting an 80.00% increase from the previous year-end due to capital reserve conversion[4] - The total number of common shareholders at the end of the reporting period is 10,338[10] - The largest shareholder, Sun Tiansong, holds 30.24% of shares, totaling 44,918,642 shares[10] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥988,612,337.01, a decrease of 1.06% from the end of the previous year[3] - Total current assets decreased to ¥711,653,853.04 from ¥767,208,962.30, a decline of 7.3%[20] - Total non-current assets increased to ¥276,958,483.97 from ¥232,036,849.77, a growth of 19.4%[20] - Total liabilities decreased to ¥49,347,953.85 from ¥66,658,603.19, a reduction of 26.0%[21] - The company's cash and cash equivalents were ¥123,118,317.79, down from ¥202,292,031.68, a decline of 39.1%[20] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥61,530,897.19, an increase of 9.11%[3] - Cash inflow from operating activities totaled ¥334,346,992.91, an increase from ¥274,217,537.37 in the previous period, representing a growth of approximately 22%[26] - Net cash flow from operating activities was ¥61,530,897.19, compared to ¥56,393,678.63 in the previous period, indicating an increase of about 9%[26] - Cash inflow from investment activities was ¥1,093,542,173.35, significantly higher than ¥251,990,382.78 in the previous period[27] - The company reported a total cash outflow from financing activities of ¥79,596,745.85, compared to ¥9,070,000.00 in the previous period[27] Research and Development - Research and development expenses for the year-to-date period rose by 66.40% to ¥21,408,593.71, driven by increased R&D projects[8] - Research and development expenses for Q3 2021 were ¥21,408,593.71, compared to ¥12,866,028.45 in Q3 2020, an increase of 66.5%[23] Shareholder Information - The company has 61,887,692 restricted shares at the beginning of the period, with 15,960,432 shares released during the period, resulting in 95,437,413 restricted shares at the end[14] - The company adjusted the number of restricted stock grants from 820,000 to 1,476,000 shares, with the grant price reduced from 30.00 CNY to 16.11 CNY[15] - The company's registered capital increased from 82,517,692.00 CNY to 148,531,845.00 CNY after the equity distribution[16] - A total of 23,291,338 shares were released from restrictions on July 27, 2021, including 15,960,432 shares available for circulation[17] - The top ten shareholders hold significant stakes, with the second-largest shareholder holding 12.10%[10] Accounting and Reporting - The report for the third quarter was not audited, indicating preliminary figures[33] - The company is implementing new leasing standards affecting the financial statements, indicating a strategic adjustment in accounting practices[28] - The company has implemented new leasing standards effective from January 1, 2021, impacting financial reporting[33]